Safety and Efficacy Trial of a RNActive-Derived Prostate Cancer Vaccine in Hormone Refractory Disease.
Phase of Trial: Phase I/II
Latest Information Update: 07 Jul 2015
At a glance
- Drugs CV 9103 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors CureVac
- 07 Jul 2015 As per a CureVac media release, results from this trial were published in the Journal for ImmunoTherapy of Cancer.
- 07 Jul 2015 Results published in a CureVac Media Release.
- 26 Jul 2013 Planned end date changed from 1 Dec 2012 to Sep 2013 as reported by ClinicalTrials.gov.